Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRON Cronos Group	$2.01 -2.0%	$1.99	$1.60 ▼ $2.54	$775.22M	1.03	1.37 million shs	1.78 million shs
EPRX Eupraxia Pharmaceuticals	$5.29 -2.2%	$4.49	$2.20 ▼ $6.20	$190.13M	1.55	13,531 shs	4,195 shs
OCS Oculis	$17.50 -3.7%	$18.89	$10.79 ▼ $23.08	$764.08M	0.29	45,381 shs	30,665 shs
QURE uniQure	$14.99 -1.4%	$14.76	$4.45 ▼ $19.18	$821.09M	0.08	1.43 million shs	1.79 million shs

The Next 7 Blockbuster Stocks for Growth Investors

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRON Cronos Group	0.00%	-3.83%	+5.24%	+13.56%	-17.96%
EPRX Eupraxia Pharmaceuticals	0.00%	-2.74%	+24.76%	+59.82%	+103.46%
OCS Oculis	0.00%	-3.10%	-10.16%	-4.21%	+49.19%
QURE uniQure	0.00%	+4.10%	-0.73%	+15.31%	+76.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRON Cronos Group	2.0719 of 5 stars	0.0	4.0	0.0	0.0	2.6	0.0	2.5
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OCS Oculis	1.5603 of 5 stars	3.5	3.0	0.0	0.0	0.0	0.0	0.6
QURE uniQure	1.7932 of 5 stars	3.5	1.0	0.0	0.0	0.6	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRON Cronos Group	0.00	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	3.20	Buy	$11.00	107.94% Upside
OCS Oculis	3.00	Buy	$35.33	101.90% Upside
QURE uniQure	2.91	Moderate Buy	$37.82	152.29% Upside

Current Analyst Ratings Breakdown

Latest EPRX, CRON, QURE, and OCS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/16/2025	EPRX Eupraxia Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Speculative Buy
5/30/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00
5/29/2025	QURE uniQure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00
5/19/2025	QURE uniQure	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	QURE uniQure	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$28.00 ➝ $28.00
5/12/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
5/9/2025	OCS Oculis	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$28.00 ➝ $33.00
5/6/2025	QURE uniQure	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/21/2025	QURE uniQure	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$70.00 ➝ $70.00

(Data available from 7/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRON Cronos Group	$117.61M	6.59	$0.00 per share	4,319.61	$2.90 per share	0.69
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
OCS Oculis	$780K	979.55	N/A	N/A	$1.91 per share	9.16
QURE uniQure	$27.12M	30.28	N/A	N/A	($0.14) per share	-107.07

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRON Cronos Group	$41.08M	$0.13	15.46	67.00	N/A	39.69%	-0.07%	-0.07%	8/6/2025 (Estimated)
EPRX Eupraxia Pharmaceuticals	-$25.50M	-$0.76	N/A	N/A	N/A	N/A	-367.73%	-112.23%	8/6/2025 (Estimated)
OCS Oculis	-$97.43M	-$2.64	N/A	N/A	N/A	-13,788.70%	-92.95%	-70.03%	8/26/2025 (Estimated)
QURE uniQure	-$239.56M	-$4.39	N/A	N/A	N/A	-1,077.05%	-483.87%	-34.28%	8/7/2025 (Estimated)

Latest EPRX, CRON, QURE, and OCS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	CRON Cronos Group	-$0.02	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	QURE uniQure	-$0.89	N/A	N/A	N/A	N/A	N/A
8/6/2025	N/A	EPRX Eupraxia Pharmaceuticals	-$0.21	N/A	N/A	N/A	N/A	N/A
5/9/2025	Q1 2025	QURE uniQure	-$1.07	-$0.82	+$0.25	-$0.82	$5.93 million	$1.57 million
5/8/2025	Q1 2025	CRON Cronos Group	$0.01	$0.02	+$0.01	$0.02	$45.44 million	$33.62 million
5/8/2025	Q1 2025	OCS Oculis	-$0.51	-$0.77	-$0.26	-$0.77	$0.22 million	$0.32 million
5/6/2025	Q1 2025	EPRX Eupraxia Pharmaceuticals	-$0.19	-$0.21	-$0.02	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
OCS Oculis	N/A	N/A	N/A	N/A	N/A
QURE uniQure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRON Cronos Group	N/A	27.80	26.75
EPRX Eupraxia Pharmaceuticals	N/A	11.10	11.10
OCS Oculis	N/A	4.79	4.79
QURE uniQure	1.53	11.99	11.99

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRON Cronos Group	8.71%
EPRX Eupraxia Pharmaceuticals	N/A
OCS Oculis	22.30%
QURE uniQure	78.83%

Insider Ownership

Company	Insider Ownership
CRON Cronos Group	7.30%
EPRX Eupraxia Pharmaceuticals	N/A
OCS Oculis	N/A
QURE uniQure	4.79%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRON Cronos Group	450	385.68 million	357.53 million	Optionable
EPRX Eupraxia Pharmaceuticals	29	35.96 million	N/A	N/A
OCS Oculis	2	43.66 million	N/A	Not Optionable
QURE uniQure	500	54.78 million	52.15 million	Optionable

EPRX, CRON, QURE, and OCS Headlines

Recent News About These Companies

uniQure: Price And Value Have Caught Up

June 17, 2025 | seekingalpha.com

uniQure Announces Appointment of Kylie O'Keefe as Chief Customer and Strategy Officer

June 11, 2025 | globenewswire.com

uniQure Provides Regulatory Update on AMT-130 for Huntington's Disease

June 2, 2025 | globenewswire.com

3 Top Genomics Stocks to Add to Your Portfolio in 2025

May 21, 2025 | zacks.com

Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High?

May 14, 2025 | zacks.com

uniQure N.V. (QURE) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates

May 9, 2025 | zacks.com

uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress

May 9, 2025 | globenewswire.com

uniQure to Announce First Quarter 2025 Financial Results

May 5, 2025 | globenewswire.com

uniQure (QURE) Moves 38.5% Higher: Will This Strength Last?

April 21, 2025 | zacks.com

uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold

April 21, 2025 | seekingalpha.com

uniQure: Bullish On Near-Term Catalysts After Breakthrough Therapy Designation For AMT-130

April 21, 2025 | seekingalpha.com

uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington's Disease

April 17, 2025 | globenewswire.com

UniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates

February 27, 2025 | zacks.com

uniQure Announces 2024 Financial Results and Highlights Recent Company Progress

February 27, 2025 | globenewswire.com

uniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years

February 7, 2025 | benzinga.com

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B

February 7, 2025 | prnewswire.com

uniQure Announces Completion of Enrollment in the First Cohort and Favorable Recommendation from the Independent Data Monitoring Committee for its Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

February 3, 2025 | globenewswire.com

uniQure Announces Favorable Recommendation from Independent Data Monitoring Committee for its Phase I/II EPISOD1 Clinical Trial of AMT-162 for the Treatment of SOD1-ALS

January 30, 2025 | globenewswire.com

uniQure Announces Pricing of its Public Offering

January 8, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Tech Stocks Poised for Explosive EPS Growth in 2025
By Gabriel Osorio-Mazilli | July 8, 2025
View 3 Tech Stocks Poised for Explosive EPS Growth in 2025
Micron Insiders Sell But Investors Should Buy, Buy, Buy
By Thomas Hughes | July 7, 2025
View Micron Insiders Sell But Investors Should Buy, Buy, Buy
Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming
By Thomas Hughes | June 26, 2025
View Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming
Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook
By Leo Miller | July 3, 2025
View Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook

EPRX, CRON, QURE, and OCS Company Descriptions

Cronos Group NASDAQ:CRON

$2.01 -0.04 (-1.95%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$2.00 -0.01 (-0.75%)

As of 07/18/2025 07:59 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$5.29 -0.12 (-2.22%)

Closing price 07/18/2025 03:50 PM Eastern

Extended Trading

$5.34 +0.05 (+0.95%)

As of 07/18/2025 07:48 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Oculis NASDAQ:OCS

$17.50 -0.67 (-3.69%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$17.55 +0.05 (+0.29%)

As of 07/18/2025 07:55 PM Eastern

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. The company is based in Zug, Switzerland.

uniQure NASDAQ:QURE

$14.99 -0.21 (-1.38%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$14.94 -0.04 (-0.30%)

As of 07/18/2025 07:28 PM Eastern

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time